ATE397016T1 - Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen - Google Patents

Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen

Info

Publication number
ATE397016T1
ATE397016T1 AT04743834T AT04743834T ATE397016T1 AT E397016 T1 ATE397016 T1 AT E397016T1 AT 04743834 T AT04743834 T AT 04743834T AT 04743834 T AT04743834 T AT 04743834T AT E397016 T1 ATE397016 T1 AT E397016T1
Authority
AT
Austria
Prior art keywords
rasgap
cancer cells
derived peptide
targeted killing
peptide
Prior art date
Application number
AT04743834T
Other languages
English (en)
Inventor
Christian Widmann
Jiang-Yang Yang
David Michod
Original Assignee
Univ Lausanne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Lausanne filed Critical Univ Lausanne
Application granted granted Critical
Publication of ATE397016T1 publication Critical patent/ATE397016T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C07K14/4706—Guanosine triphosphatase activating protein, GAP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT04743834T 2003-06-30 2004-06-30 Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen ATE397016T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48369103P 2003-06-30 2003-06-30

Publications (1)

Publication Number Publication Date
ATE397016T1 true ATE397016T1 (de) 2008-06-15

Family

ID=33552068

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04743834T ATE397016T1 (de) 2003-06-30 2004-06-30 Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen

Country Status (16)

Country Link
US (1) US8110544B2 (de)
EP (1) EP1641820B1 (de)
JP (1) JP4887143B2 (de)
KR (1) KR101051785B1 (de)
CN (1) CN1816564B (de)
AT (1) ATE397016T1 (de)
AU (1) AU2004251126B2 (de)
BR (1) BRPI0411485A (de)
CA (1) CA2530613A1 (de)
DE (1) DE602004014145D1 (de)
DK (1) DK1641820T3 (de)
EA (1) EA009524B1 (de)
ES (1) ES2308200T3 (de)
IL (1) IL172783A (de)
MX (1) MXPA05014078A (de)
WO (1) WO2005000887A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1641820T3 (da) * 2003-06-30 2008-09-15 Univ Lausanne Fra RasGap afledt peptid til selektiv at dræbe kræftceller
US7579319B2 (en) * 2004-12-06 2009-08-25 The Regents Of The University Of California Methods for improving the structure and function of arterioles
JP2010507361A (ja) 2006-07-31 2010-03-11 キュアバック ゲーエムベーハー 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
EP1892248A1 (de) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Bindeproteine mit spezifischer und hoher Affinität enthaltend modifizierte SH3-Domänen von FYN-Kinasen
US9689879B2 (en) 2006-08-21 2017-06-27 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
US9513296B2 (en) 2006-08-21 2016-12-06 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
CN101932707B (zh) 2008-01-31 2013-08-21 库瑞瓦格有限责任公司 作为免疫刺激剂/佐剂的式(I)(NuGlXmGnNv)a的核酸及其衍生物
WO2010037284A1 (zh) * 2008-09-26 2010-04-08 武汉凯泰新生物技术有限公司 治疗或预防癌症的多肽及其衍生产品和应用
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010097720A1 (en) * 2009-01-30 2010-09-02 Universite De Lausanne Use of a fragment of rasgap peptide in the treatment or prevention of metastasis
CN101891802B (zh) * 2009-08-11 2011-11-16 武汉凯泰新生物技术有限公司 治疗或预防癌症的多肽或衍生产品及其应用
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
CN101921313B (zh) * 2010-04-07 2012-02-29 武汉凯泰新生物技术有限公司 治疗或预防癌症的多肽或其衍生产品及应用
US8968746B2 (en) 2010-07-30 2015-03-03 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
EP2600886A1 (de) * 2010-08-02 2013-06-12 Université de Lausanne Verwendung eines peptids zur verstärkung der krebszellentötungskapazität einer strahlentherapie
CN102533996B (zh) * 2012-01-04 2013-06-05 南通大学附属医院 确定人april基因启动子、转录因子结合位点的方法及用途
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
CA2915728A1 (en) 2013-08-21 2015-02-26 Thomas Kramps Respiratory syncytial virus (rsv) vaccine
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694296B1 (fr) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibant l'activité des protéines ras, préparation et utilisation.
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
FR2780062B1 (fr) 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
EP1137664A2 (de) * 1998-12-10 2001-10-04 Washington University Protein-transduktionssystem und methoden seiner verwendung
CA2364690A1 (en) * 1999-02-28 2000-10-19 Washington University Novel transduction molecules and methods for using same
AUPR721101A0 (en) 2001-08-23 2001-09-13 University Of Queensland, The Nucleic acid and polypeptide linked to breast cancer
DK1641820T3 (da) * 2003-06-30 2008-09-15 Univ Lausanne Fra RasGap afledt peptid til selektiv at dræbe kræftceller

Also Published As

Publication number Publication date
JP2007527856A (ja) 2007-10-04
AU2004251126A1 (en) 2005-01-06
EA200600128A1 (ru) 2006-08-25
EP1641820A1 (de) 2006-04-05
JP4887143B2 (ja) 2012-02-29
IL172783A (en) 2011-12-29
IL172783A0 (en) 2006-06-11
KR20060030486A (ko) 2006-04-10
US20060234929A1 (en) 2006-10-19
EP1641820B1 (de) 2008-05-28
BRPI0411485A (pt) 2006-07-25
AU2004251126B2 (en) 2009-11-12
MXPA05014078A (es) 2006-05-25
HK1089190A1 (en) 2006-11-24
ES2308200T3 (es) 2008-12-01
DE602004014145D1 (de) 2008-07-10
US8110544B2 (en) 2012-02-07
CN1816564B (zh) 2010-11-24
CN1816564A (zh) 2006-08-09
DK1641820T3 (da) 2008-09-15
CA2530613A1 (en) 2005-01-06
WO2005000887A1 (en) 2005-01-06
EA009524B1 (ru) 2008-02-28
KR101051785B1 (ko) 2011-07-26

Similar Documents

Publication Publication Date Title
DE602004014145D1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
EP2537524A3 (de) Behandlung von T-Zell-vermittelten Krankheiten
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
EA200501702A1 (ru) Устойчивая к манипуляциям дозировочная форма для трансдермального введения
CY1113299T1 (el) Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
CY1113948T1 (el) Θεραπευτικα δραστικα αλφα-msh αναλογα
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
EP1651676A4 (de) Glucan zur verbesserung der therapie
EA200702656A1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение
EA200602137A1 (ru) Гидрогелевые препараты интерферона
WO2007046103A3 (en) System for iontophoretic transdermal delivery of polymeric agents and methods of use thereof
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
ATE549353T1 (de) Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
CY1114724T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
ATE495753T1 (de) Zusammensetzung zur transmukosalen abgabe von polypeptiden
AR044209A1 (es) Composiciones farmaceuticas que comprenden epinastina para el tratamiento de enfermedades de la piel
CY1123728T1 (el) (2r,4r)-5-(5'-χλωρο-2'-φθοροδιφαινυλ-4-υλ) -2-υδροξυ-4- [(5-μεθυλοξαζολο-2-καρβονυλ) αμινο] πεντανοϊκο οξυ
ATE458750T1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
NO20055209D0 (no) Peptabody for cancerbehandling
ATE401400T1 (de) Antiangiogene peptide zur behandlung oder vorbeugung von endometriose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1641820

Country of ref document: EP